These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 33069129)

  • 1. Design, synthesis and biological activity of bicyclic carboxamide derivatives as TRK inhibitors.
    Sun M; Cai S; Li P; Zhang F; Zhang H; Zhou J
    Bioorg Med Chem; 2020 Dec; 28(23):115811. PubMed ID: 33069129
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, synthesis and biological evaluation of macrocyclic derivatives as TRK inhibitors.
    Li P; Cai S; Zhao T; Xu L; Guan D; Li J; Zhou J; Zhang H
    Bioorg Med Chem Lett; 2021 Dec; 53():128409. PubMed ID: 34628036
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, synthesis, and Structure-Activity Relationships (SAR) of 3-vinylindazole derivatives as new selective tropomyosin receptor kinases (Trk) inhibitors.
    Duan Y; Wang J; Zhu S; Tu ZC; Zhang Z; Chan S; Ding K
    Eur J Med Chem; 2020 Oct; 203():112552. PubMed ID: 32702585
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of novel indazole derivatives as second-generation TRK inhibitors.
    Qin Q; Lu S; Guo Z; Li Z; Fu Q; Wang X; Wu T; Sun Y; Liu N; Zhang H; Zhao D; Cheng M
    Eur J Med Chem; 2024 Oct; 276():116640. PubMed ID: 39033612
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of pyrazolo-thieno[3,2-d]pyrimidinylamino-phenyl acetamides as type-II pan-tropomyosin receptor kinase (TRK) inhibitors: Design, synthesis, and biological evaluation.
    Yan W; Zhang L; Lv F; Moccia M; Carlomagno F; Landry C; Santoro M; Gosselet F; Frett B; Li HY
    Eur J Med Chem; 2021 Apr; 216():113265. PubMed ID: 33652352
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design and synthesis of novel orally selective and type II pan-TRK inhibitors to overcome mutations by property-driven optimization.
    Li MC; Lin WH; Wang PC; Su YC; Chen PY; Fan CM; Chen CP; Huang CL; Chiu CH; Chang L; Chen CT; Yeh TK; Hsieh HP
    Eur J Med Chem; 2021 Nov; 224():113673. PubMed ID: 34303872
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanisms of Resistance to NTRK Inhibitors and Therapeutic Strategies in NTRK1-Rearranged Cancers.
    Fuse MJ; Okada K; Oh-Hara T; Ogura H; Fujita N; Katayama R
    Mol Cancer Ther; 2017 Oct; 16(10):2130-2143. PubMed ID: 28751539
    [No Abstract]   [Full Text] [Related]  

  • 8. Design, synthesis, and biological evaluation of aminopyridine derivatives as novel tropomyosin receptor kinase inhibitors.
    Lv R; Wang X; Sun Y; Qin Q; Liu N; Wu T; Sun Y; Yin W; Zhao D; Cheng M
    Arch Pharm (Weinheim); 2023 Mar; 356(3):e2200438. PubMed ID: 36398500
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting TRK family proteins in cancer.
    Khotskaya YB; Holla VR; Farago AF; Mills Shaw KR; Meric-Bernstam F; Hong DS
    Pharmacol Ther; 2017 May; 173():58-66. PubMed ID: 28174090
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural Optimization and Structure-Activity Relationship Studies of 6,6-Dimethyl-4-(phenylamino)-6
    Pan S; Zhang L; Luo X; Nan J; Yang W; Bin H; Li Y; Huang Q; Wang T; Pan Z; Mu B; Wang F; Tian C; Liu Y; Li L; Yang S
    J Med Chem; 2022 Feb; 65(3):2035-2058. PubMed ID: 35080890
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of novel 3-(1H-pyrazol-4-yl)-1H-indazole derivatives as potent type II TRK inhibitors against acquired resistance.
    Qin Q; Guo Z; Lu S; Wang X; Fu Q; Wu T; Sun Y; Liu N; Zhang H; Zhao D; Cheng M
    Eur J Med Chem; 2024 Jan; 264():115953. PubMed ID: 38029466
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design and synthesis of a fluorinated quinazoline-based type-II Trk inhibitor as a scaffold for PET radiotracer development.
    Bernard-Gauthier V; Mahringer A; Vesnaver M; Fricker G; Schirrmacher R
    Bioorg Med Chem Lett; 2017 Jun; 27(12):2771-2775. PubMed ID: 28476569
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of the Next-Generation Pan-TRK Kinase Inhibitors for the Treatment of Cancer.
    Liu Z; Yu P; Dong L; Wang W; Duan S; Wang B; Gong X; Ye L; Wang H; Tian J
    J Med Chem; 2021 Jul; 64(14):10286-10296. PubMed ID: 34253025
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pyrizolo[1,5-a]pyrimidine derivatives of the second-generation TRK inhibitor: Design, synthesis and biological evaluation.
    Fan Y; Zhang Y; Liu Y; Jiang H; Zhou Y; Tang C; Fan W
    Bioorg Med Chem Lett; 2022 May; 63():128646. PubMed ID: 35231576
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel in-cell ELISA method for screening of compounds inhibiting TRKA phosphorylation, using KM12 cell line harboring TRKA rearrangement.
    Pandre MK; Shaik S; Satya Pratap VVV; Yadlapalli P; Yanamandra M; Mitra S
    Anal Biochem; 2018 Mar; 545():78-83. PubMed ID: 29360440
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acquired NF2 mutation confers resistance to TRK inhibition in an ex vivo LMNA::NTRK1-rearranged soft-tissue sarcoma cell model.
    Chen Y; Steiner S; Hagedorn C; Kollar S; Pliego-Mendieta A; Haberecker M; Plock J; Britschgi C; Planas-Paz L; Pauli C
    J Pathol; 2024 Jun; 263(2):257-269. PubMed ID: 38613194
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis and evaluate of indazolylaminoquinazoline derivatives as potent Tropomyosin receptor kinase (TRK) inhibitors.
    Xu Y; Zhao W; Zhang X; Yu X; Chen Y; Wang Z; Chu Y; Zhu X; Zhang P
    Bioorg Med Chem; 2024 Feb; 99():117608. PubMed ID: 38271867
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis, anticancer, and docking studies of salicyl-hydrazone analogues: A novel series of small potent tropomyosin receptor kinase A inhibitors.
    Alam MS; Choi SU; Lee DU
    Bioorg Med Chem; 2017 Jan; 25(1):389-396. PubMed ID: 27856237
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure-Based Optimization of the Third Generation Type II Macrocycle TRK Inhibitors with Improved Activity against Solvent-Front, xDFG, and Gatekeeper Mutations.
    Wang Z; Wang J; Wang Y; Xiang S; Zhou H; Song S; Song X; Tu Z; Zhou Y; Ding K; Zhang ZM; Zhang Z; Lu X
    J Med Chem; 2023 Sep; 66(18):12950-12965. PubMed ID: 37676745
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of (E)-N-(4-methyl-5-(3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thiazol-2-yl)-2-(4-methylpiperazin-1-yl)acetamide (IHMT-TRK-284) as a novel orally available type II TRK kinase inhibitor capable of overcoming multiple resistant mutants.
    Wang B; Zhang W; Liu X; Zou F; Wang J; Liu Q; Wang A; Hu Z; Chen Y; Qi S; Jiang Z; Chen C; Hu C; Wang L; Wang W; Liu Q; Liu J
    Eur J Med Chem; 2020 Dec; 207():112744. PubMed ID: 32949955
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.